Apimeds Pharmaceuticals US APUS
NYSE APUS
$4.16 -0.23 (-5.21%)
At close: Aug 20, 2026 · 11:16 AM UTC

Apimeds Pharmaceuticals US (APUS) Operating Expenses (2024 - 2025)

Apimeds Pharmaceuticals US's (APUS) quarterly Operating Expenses came in at $7.0 million in Q4 2025, up 2454.32% YoY from $275613.0 in Q4 2024, and up 281.73% on a QoQ basis from $1.8 million in Q3 2025.

Apimeds Pharmaceuticals US (APUS) Operating Expenses (2024 - 2025) Analysis & Trends

Apimeds Pharmaceuticals US (APUS) has 2 years of Operating Expenses data on file, last reported at $7.0 million in Q4 2025.

  • Quarterly Operating Expenses rose 2454.32% year-over-year to $7.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $11.9 million (up 834.25% YoY) and the FY2025 annual result came in at $11.9 million, up 834.25% from the prior year.
  • Operating Expenses grew to $7.0 million in Q4 2025, from $1.8 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $7.0 million in Q4 2025 to a low of $271726.0 in Q1 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Opex (Qtr)
1 Haleon 44.07 Bn 43.10 Bn - -
2 Teva Pharmaceutical Industries 43.42 Bn 39.76 Bn 2.15 Bn 1.29 Bn
3 Zoetis 31.86 Bn 30.18 Bn 1.05 Bn 215.00 Mn
4 Takeda Pharmaceutical 28.77 Bn 22.98 Bn 5.10 Bn -2.85 Bn
5 United Therapeutics 22.29 Bn 19.63 Bn 683.80 Mn 452.50 Mn
6 Viatris 18.78 Bn 17.89 Bn 1.46 Bn 1.45 Bn
7 Neurocrine Biosciences 15.66 Bn 15.27 Bn 935.80 Mn 807.50 Mn
8 Elanco Animal Health 11.91 Bn 11.38 Bn 798.00 Mn 550.00 Mn
9 Dr Reddys Laboratories 10.16 Bn 10.00 Bn - -
10 Apimeds Pharmaceuticals US 7.12 Mn 7.12 Mn - 6.28 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 7.04 Mn
Sep 30, 2025 1.84 Mn
Jun 30, 2025 2.66 Mn
Mar 31, 2025 364,368.00
Dec 31, 2024 275,613.00
Sep 30, 2024 299,999.00
Jun 30, 2024 427,757.00
Mar 31, 2024 271,726.00